Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 15/20 | 0.60 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259044 | 1.00 | MAPK1 (0.60) | MAPK1RIPK1AXLPRKCIALDH1A1 | |
| SCHEMBL2967092 | 0.83 | MAPK1 (0.48) | MAPK1RIPK1AXLPRKCIALDH1A1 | |
| SCHEMBL650127 | 0.76 | MAPK1 (0.56) | MAPK1RIPK1AXLJAK3JAK2 | |
| SCHEMBL421369 | 0.75 | MAPK1 (1.00) | MAPK1RIPK1PRKCIJAK3JAK2 | |
| SCHEMBL21821052 | 0.75 | MAPK1 (0.60) | MAPK1RIPK1JAK3JAK2JAK1 | |
| SCHEMBL12657772 | 0.75 | MAPK1 (0.60) | MAPK1RIPK1AXLPIK3CDPIK3CA | |
| SCHEMBL2619257 | 0.75 | MAPK1 (0.60) | MAPK1RIPK1AXLPRKCIJAK3 | |
| SCHEMBL20674184 | 0.75 | MAPK1 (0.66) | MAPK1RIPK1JAK3JAK2JAK1 | |
| SCHEMBL10113284 | 0.75 | MAPK1 (0.60) | MAPK1RIPK1AXLPIK3CDPIK3CA | |
| SCHEMBL9989891 | 0.75 | MAPK1 (0.60) | MAPK1RIPK1AXLPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117263942-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-112166110-B | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| CN-108727369-B | Influenza virus replication inhibitors and uses thereof | 广东东阳光药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-101817823-A | Preparation method of 4,7-diazaindole and 5-site substitute thereof | SHANGHAI BEPHARM SCIENCE & TECHNOLOGY CO LTD | 2010-09-01 | — | — | CN | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106444-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106444-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| CN-101098872-A | Pyrrolopyrazines and pyrazolopyrazines useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2008-01-02 | — | — | CN | disclosed |
| EP-1814882-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060258662-A1 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-16 | — | — | US | disclosed |
| WO-2006058074-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885RIPK1 910/4885AXL 1258/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885RIPK1 910/4885AXL 1258/4885 |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | MAPK1 431/4885RIPK1 228/4885AXL 385/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885RIPK1 910/4885AXL 1258/4885 |
| US-20060258662-A1 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | AURKC, AURKA, PLK1 | MAPK1 390/4885RIPK1 377/4885AXL 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.